Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-γ agonist trifarotene.

Author: AubertJ, BertinoB, Blanchet-RéthoréS, CarlavanI, DrenoB, DéretS, GamboaB, JomardA, LuzyA P, MauvaisP, MounierC, PascauJ, PelissonI, PiwnicaD, PortalT, RivierM, RossioP, ThoreauE, VialE, VoegelJ J

Paper Details 
Original Abstract of the Article :
BACKGROUND: First- and third-generation retinoids are the main treatment for acne. Even though efficacious, they lack full selectivity for retinoic acid receptor (RAR) γ, expressed in the epidermis and infundibulum. OBJECTIVES: To characterize the in vitro metabolism and the pharmacology of the nov...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1111/bjd.16719

データ提供:米国国立医学図書館(NLM)

Trifarotene: A Selective Retinoid Receptor Agonist for Acne Treatment

Acne, a common skin condition that affects millions, is like a desert storm of irritation and blemishes. The search for effective treatments is an ongoing quest, and this research takes us on a journey to explore a new weapon in the fight against acne, a novel retinoid called trifarotene. This study delves into the pharmacological properties of trifarotene, investigating its selectivity for different types of retinoic acid receptors (RARs), its activity on the expression of retinoid target genes, and its potential for topical application. The authors' objective is to uncover the effectiveness and safety of trifarotene as a topical treatment for acne.

Unlocking the Power of Trifarotene

The authors have identified trifarotene as a potent and selective RARγ agonist, making it a promising candidate for acne treatment. They found that trifarotene is active and stable in keratinocytes (skin cells) but rapidly metabolized in the liver, suggesting a favorable safety profile. In vivo studies have shown that topical application of trifarotene is highly comedolytic (reducing blackheads and whiteheads), anti-inflammatory, and antipigmenting. These promising results suggest that trifarotene could be a valuable addition to the acne treatment arsenal.

Implications for Acne Treatment

This research is a welcome addition to the desert of acne treatment options. The authors' work highlights the potential of trifarotene, a selective RARγ agonist, to effectively combat acne. Its rapid degradation in the liver is a reassuring sign of its safety, potentially leading to fewer side effects. Further studies are needed to confirm the long-term efficacy and safety of trifarotene in treating acne, but the initial findings are promising.

Dr. Camel's Conclusion

The discovery of trifarotene, a selective RARγ agonist, is a beacon of hope for those battling acne. This promising new treatment holds the potential to clear the desert of blemishes and improve skin health. The authors' research is a testament to the power of innovation in the field of dermatology, offering new solutions for a common and often frustrating skin condition.

Date :
  1. Date Completed 2019-11-25
  2. Date Revised 2023-12-13
Further Info :

Pubmed ID

29974453

DOI: Digital Object Identifier

10.1111/bjd.16719

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.